Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

FI: 4,964
Type: Article

Home · Ee11-Immune-mediated Skin Diseases (Emerging)

Artículo original

Year: 2022

Brands

Ruiz-Villaverde, R; Fernandez-Freire, LR; Font-Ugalde, P; Galan-Gutierrez, M

Magazine

Title: JOURNAL OF CLINICAL MEDICINE

Quartile

Q2